- Home
- TONT vs AARD Comparison
TONT vs AARD Comparison
Compare TONT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$7.25
Company Overview
Basic Information| Metric | TONT | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.6M | 165.8M |
| IPO Year | 2024 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TONT | AARD |
|---|---|---|
| Price | $10.86 | $7.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 184.5K | 114.1K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.81 | $3.35 |
| 52 Week High | $10.90 | $17.94 |
Technical Indicators
Market Signals| Indicator | TONT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 49.87 |
| Support Level | $10.81 | $4.99 |
| Resistance Level | $10.90 | $8.02 |
| Average True Range (ATR) | 0.01 | 0.83 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 55.56 | 30.93 |
Price Performance
Historical Comparison TONT
AARD
About TONT Graf Global Corp. Class A ordinary shares
Graf Global Corp is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.